OrthoPediatrics Corp. develops and commercializes medical devices for pediatric orthopedics, with products used in trauma and deformity, scoliosis, sports medicine and related procedures. Company news commonly covers quarterly financial results, revenue by product category, domestic and international sales trends, cash-flow metrics and updates to financial guidance.
Recurring product and market updates include specialty bracing, spine and deformity correction systems, implants, instruments and enabling technologies for pediatric care. Announcements also include investor conference participation and portfolio additions such as hospital-based traction systems and other products aimed at children with orthopedic conditions.
OrthoPediatrics (KIDS) expanded its specialty bracing portfolio with the launch of Knee 'TractorFIX, a brace intended to manage pediatric knee contractures.
The brace is intended for patients approximately 2 to 21 years of age with pre-existing or developing knee contractures who are undergoing tibial treatment with an external fixator. It connects directly to the external fixator to support contracture management during treatment. OrthoPediatrics describes the product as a standardized alternative to custom-built solutions and pairs it with its ORTHEX external fixation platform.
OrthoPediatrics (KIDS) sponsored the 10th Pediatric Orthopedic Surgical Techniques Course, held September 18–19, 2026, in Memphis, Tennessee. The company served as primary and Platinum Sponsor. The course drew a record 39 participants from 23 institutions across 22 cities and three countries. Designed for senior residents, fellows and early-career surgeons, it combined instruction with hands-on learning and introduced a companion manual.
OrthoPediatrics (KIDS) reports more than 1,000 implantations of its PNP Tibia Nail system in pediatric patients as of September 22, 2026.
The system features a 7mm cannulated rigid tibial nail, described as the only product of its size, with implants available in 7mm–12mm diameters. Nearly 20% of all OrthoPediatrics tibia nails implanted have been the smallest 7mm size. PNP Tibia is currently offered in five markets, with a European launch planned for 2027.
OrthoPediatrics (Nasdaq: KIDS) announced the full commercial launch of its 3P™ Pediatric Plating Platform® Hip System in the United States after a limited launch that included more than 350 surgical implantations. The pediatric-specific system targets proximal femur trauma and deformity correction.
The 3P Hip System, the first product in the broader Pediatric Plating Platform portfolio, offers advanced implant and instrumentation technologies designed to enhance fixation options, streamline surgical workflow, and support procedures across Infant, Child, and Adolescent patient groups. According to OrthoPediatrics, this launch is a key milestone for its Trauma & Deformity business and establishes the foundation for additional plating systems intended to expand treatment options for pediatric orthopedic surgeons worldwide.
OrthoPediatrics (Nasdaq: KIDS) reported second quarter 2026 revenue of $70.5 million, up 15% year-over-year and its first quarter above $70 million. U.S. revenue rose 14% to $54.8 million, international revenue grew 22% to $15.7 million, and Trauma & Deformity sales increased 26% to $52.6 million, while Scoliosis declined 9% to $16.9 million.
Gross margin expanded to 74% from 72%, with operating expenses up 3%. Adjusted EBITDA reached a record $6.8 million versus $4.1 million, and quarterly free cash flow usage improved 78% to $3.1 million. The company raised 2026 revenue guidance to $265–$269 million and maintained expectations for about $25 million adjusted EBITDA and breakeven free cash flow. OrthoPediatrics also announced an exclusive U.S. distribution agreement with OSSIO for bio-integrative, metal-free fixation technology.
OrthoPediatrics (Nasdaq: KIDS) announced that President & CEO Dave Bailey and COO & CFO Fred Hite will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA. The session is scheduled for Wednesday, August 12, 2026, at 9:00 a.m. ET.
An audio webcast of the fireside chat will be available on OrthoPediatrics’ investor relations website at http://ir.orthopediatrics.com, with a replay accessible after the event.
OrthoPediatrics (Nasdaq: KIDS) will release its second quarter 2026 financial results on Tuesday, August 4, 2026, after the market close. The company will host a conference call the same day at 4:30 p.m. ET, with a live and archived webcast available on its website for at least 90 days.
OrthoPediatrics (Nasdaq: KIDS) announced an exclusive U.S. distribution agreement with OSSIO to supply OSSIOfiber bio-integrative, metal-free fixation implants to children’s hospitals nationwide.
The technology is designed for pediatric fractures and deformities, gradually integrating into bone within 18–24 months and aiming to reduce secondary hardware removal surgeries.
OrthoPediatrics (Nasdaq: KIDS) announced that Chief Operating Officer and Chief Financial Officer Fred Hite will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, FL.
The session is on Monday, June 8, 2026 at 2:40 pm ET and will be webcast live on the company’s investor relations website, with a replay available.
OrthoPediatrics (Nasdaq: KIDS) reported Q1 2026 revenue of $59.4M, up 13% year-over-year, with U.S. revenue of $45.3M (76%) and international revenue of $14.1M (24%).
Adjusted EBITDA was $2.2M, free cash flow usage improved 40% to $5.0M, and full-year 2026 revenue guidance was raised to $263.0M–$267.0M.